Mounjaro vs. the Alternatives: Victoza, Metformin, and Berberine, Compared

What's the best alternative to Mounjaro?

It depends on what you want to change. Start with the line that sounds like you:

• You want the same results for less cash: Zepbound from Lilly is the same medicine, about $300 to $450 a month. It is approved for weight management, not diabetes.
• Budget comes first and you don't have diabetes yet: metformin, from about $4 a month, is a sensible first step, especially with prediabetes, insulin resistance or PCOS.
• You already have type 2 diabetes: ask whether metformin belongs alongside Mounjaro. That pairing is common.
• You're stable on Victoza: no urgent reason to switch. A plateau, or wanting a weekly shot instead of a daily one, is a fair moment to ask.
• You're curious about a supplement: berberine has modest blood sugar evidence. It is not a weight-loss stand-in for a GLP-1.
• You want the strongest result: compare other GLP-1 brands instead, at Mounjaro vs. Ozempic and Mounjaro vs. Zepbound.

Is Mounjaro a GLP-1, and is anything better than it?

Yes, with a footnote. Mounjaro's medicine, tirzepatide, acts on the GLP-1 receptor like Victoza does. It also acts on a second receptor, called GIP, that none of the other options here touch.

On average weight loss, nothing on this page comes close. In SURMOUNT-1, people on 15 mg lost about 21% of their weight over 72 weeks, against about 3% on placebo. That trial used Zepbound, the same medicine approved for weight.

What does Mounjaro itself cost?

"Alternative" often means a cheaper way to a similar result, so start with Mounjaro's own prices.

• With a commercial plan that covers it for type 2 diabetes: as little as $25 a fill with Lilly's savings card, through Dec 31, 2026.
• Without coverage: Lilly sells Mounjaro for about $500 a month at any dose, through LillyDirect or the savings card.
• Zepbound, the same medicine for weight: about $300 to $450 a month from Lilly. The $450 price needs each refill within 45 days.
• On Medicare: Part D can cover Mounjaro for type 2 diabetes at your plan's copay. Medicare's $50 GLP-1 Bridge does not cover Mounjaro.
• List price, no program: about $1,110 a month. A GoodRx coupon brings it to about $1,090.

Below the brands sits compounded tirzepatide, made by a pharmacy for one patient. It is not FDA-approved, and month-to-month prices run from about $130 to $650 across sellers. Compounded Mounjaro compares sellers and explains the narrow legal basis. For every brand-name path, see Mounjaro cost.

Victoza (liraglutide) vs. Mounjaro: is the older drug worth it?

Victoza was the GLP-1 many doctors used before Mounjaro. It was approved in 2010 for type 2 diabetes. Its medicine, liraglutide, acts only on the GLP-1 receptor and needs a daily shot.

No trial has tested the two against each other. For weight, the best liraglutide data come from SCALE, at a higher 3 mg dose sold as Saxenda. People lost about 8.4 kg, roughly 18 pounds, over 56 weeks, against about 2.8 kg on placebo. Victoza's diabetes doses only go up to 1.8 mg, and Saxenda is being discontinued.

Price is where liraglutide can win. Generic liraglutide runs about $110 to $160 a month for 1.2 mg, and about $145 to $330 for 1.8 mg, with a coupon. That is often below Mounjaro or Zepbound paid in cash, for a much smaller weight effect.

Victoza makes most sense if your plan covers it and not Mounjaro, or if you are already stable on it.

Metformin vs. Mounjaro: why does an old diabetes pill keep coming up?

Metformin is not a weaker Mounjaro. It is a different drug for a related problem. It mainly tells the liver to release less sugar and helps the body use insulin better. It has been a first-line type 2 diabetes drug for decades, and the generic is cheap.

Its weight effect is small. In the Diabetes Prevention Program, people on metformin lost about 2% of their weight, against almost none on placebo, and kept it off for at least 10 years.

Its strength is diabetes prevention. In the Diabetes Prevention Program trial, metformin cut new cases of type 2 diabetes by 31% in adults at high risk. It is also a common first step for insulin resistance with PCOS.

Many people take both. Metformin works on insulin and the liver, and tirzepatide works on appetite and digestion. If cost or caution is driving your question, ask whether metformin fits as a first step or an addition.

Berberine vs. Mounjaro: is "nature's Ozempic" real?

Berberine is a plant compound sold over the counter as a supplement. It does not act on the GLP-1 or GIP receptors. It seems to work on an energy pathway inside cells called AMPK, which metformin also uses. So "nature's metformin" is the closer comparison.

The blood sugar evidence is real but modest. A 2024 review of 50 trials with about 4,150 people with type 2 diabetes found berberine alone lowered fasting blood sugar by a small amount.

The weight evidence is thin. A 2025 review of 23 randomized trials in the International Journal of Obesity found berberine lowered weight by less than a kilogram, about 2 pounds, compared with placebo.

Berberine is sold as a dietary supplement, so the FDA does not check its purity or strength before sale. Products vary by maker. Because it also lowers blood sugar, tell your prescriber before adding it to metformin, insulin or a GLP-1.

Mounjaro and its alternatives in perimenopause and menopause

No trial has tested Mounjaro, Victoza, metformin or berberine only in perimenopausal women. Falling estrogen around menopause is linked to more insulin resistance and more belly fat, which is why this group of medicines comes up so often after 40.

For how these drugs fit alongside hormone therapy, see GLP-1 medications and menopause.